We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Sulfenic Acid Test May Enhance Early Detection of Breast Cancer

By LabMedica International staff writers
Posted on 22 Sep 2009
A recent report described the development of an immunochemical test for sulfenic acid, an early indicator of oxidative stress, and a possible marker for the first stages of breast cancer.

Sulfenic acid is produced when hydrogen peroxide reacts with the amino acid cysteine. More...
Proteins that have been modified by the addition of sulfenic acid are immunochemically distinct from the original. Applying this knowledge, investigators at the University of Michigan (Ann Arbor, USA) raised specific antibodies against sulfenic acid-modified proteins. The level of such proteins is an indicator of oxidative stress, a component of the "redox profile" that metabolically distinguishes normal and cancer cells.

The antibodies were labeled with a fluorescent tag that permitted detection of antibody binding by observation under a fluorescence microscope. Results obtained by using this system to determine the level of sulfenic acid modification of proteins in breast cancer cell lines were published in the September 10, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS). The results showed that the technique could be used to monitor differences in thiol redox status and revealed a diverse pattern of sulfenic acid modifications across different subtypes of breast tumors.

"For each line, we saw a very distinct pattern of sulfenic acid modifications," said senior author Dr. Kate S. Carroll, assistant professor of chemistry at the University of Michigan. "Whether the patterns we see will correlate with response to antioxidant treatment or other therapies that modulate oxidative stress level remains to be seen, but now we at least have a way to investigate that question.
Some of the modified proteins may not play any role, but I am sure it will turn out that many of them do. Once we find out which proteins are involved, we can target them directly rather than using global treatments like antioxidants. Being able to monitor a marker of oxidative stress that is associated with the activation of tumor cell growth pathways, particularly at an early stage, and then tailor treatments accordingly would allow for more targeted studies and might improve the odds of success with antioxidants and prooxidants," said Dr. Carroll.

Related Links:

University of Michigan



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.